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ABSTRACT
Lafora disease (LD, OMIM 254780) is a fatal rare disorder characterized by epilepsy and
neurodegeneration. In the vast majority of cases LD is related to mutations in either the EPM2A
gene (encoding the glucan phosphatase laforin) or the EPM2B gene (encoding the E3-ubiquitin
ligase malin). Alterations in these genes consist of deletions or missense and nonsense
mutations. These alterations are spread all over the laforin and malin protein sequences and it
remains to be shown whether they correlate with the severity of the disease. We have recently
gained access to a primary fibroblast sample from a compound heterozygous EPM2A patient
(Y112X/N163D), who shows a slow progression of the disease. As the Y112X mutation is
related to regular progression of the disease and to our knowledge the laforin N163D mutation
is novel, here we have carried out the phenotypic characterization of the laforin N163D
mutation. We have expressed the laforin-N163D mutant in bacteria and purified the
corresponding protein. Using OMFP as substrate we have observed no major changes in
phosphatase activity. The mutant protein was also as stable as wild type when expressed either
in bacteria or in mammalian cells. However, it showed a severe impairment in the interaction
with regular laforin partners, as laforin itself, malin, R5/PTG and R6 (by yeast two-hybrid
assays). Probably, this lack of interaction is the cause of the pathogenic profile of this novel
mutation.
We have recently reported that human primary fibroblasts from LD patients have an
impairment of mitochondrial function with increased production of reactive oxygen species
(ROS). In agreement with these observations we found that primary fibroblasts from EPM2A
Y112X/N163D patient presented higher levels of superoxide and lower levels of superoxide
dismutase activity. The levels of thioredoxin1 (Trx1) were also decreased in the LD samples. All
these results indicate that primary fibroblasts from EPM2A Y112X/N163D patient suffer from
oxidative stress.
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1.- Modeling of the location of the Y112X and N163D 
mutations in laforin’ s structure
The Y112X mutation is located in the CBM domain. The N163D mutation is 
located in the DSP domain, at the entrance of the pocket containing the 
catalytic C266.
2.- Assessment of the biochemical properties of recombinant laforin N163D
The recombinant laforin N163D mutation 
was purified using amylose-sepharose
beads. The purification yield was similar as 
wild type laforin, indicating that binding to 
carbohydrates is not affected by the 
N163D mutation.
2.1.- Carbohydrate binding 
OMFP assay
2.2.- In vitro phosphatase activity
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WT 20
N163D 20 Phosphatase activity of Laforina-N163D is not 
affected, at least on small substrates. It is even 
more active that wild type.
3.- Assessment of the stability of laforin N163D 
when expressed in mammalian cells
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HA-tagged Laforin N163D was expressed in HEK293 cells. Crude extracts 
were prepared and analyzed by western blotting. The protein stability of 
laforin N163D mutant is similar as wild type.
4.- Assessment of the interaction profile of laforin 
N163D by yeast two-hybrid analysis
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Laforin N163D loses the ability to interact with itself, malin, R5/PTG and R6. 
Dimerization was done 
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5.- Primary fibroblasts from the laforin Y112X/N163D patient show oxidative stress 
dysfunctions
Superoxide (O2-) levels
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Primary fibroblasts from laforin Y112X/N163D patient show higher levels 
of superoxide anion and lower levels of superoxide dismutase activity
SOD activity
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They also show lower levels of Thioredoxin 1, a protein 
involved in maintaining proteins a reduced state
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CONCLUSIONS
• A compound heterozygous EPM2A Y112X/N163D patient 
shows a slow progression of Lafora disease.
• Primary fibroblasts from this patient show oxidative stress 
dysfunctions.
• Recombinant laforin N163D shows similar carbohydrate 
binding properties and phosphatase activity as wild type.
• Recombinant laforin N163D is as stable as wild type when 
expressed in mammalian cells.
• Recombinant laforin N163D loses its ability to interact with 
specific partners.
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